NRP2 and neoplasm: A mouse monoclonal antibody (mAb) was developed to specifically bind to pancreatic ductal adenocarcinoma cells.[18] By linking the NRP2 mAb to the surface of the GEM‐DVDMS@NH2‐MIL‐101(Fe) composite, tumor targeting was improved, enabling the drug system to quickly reach the tumor site.